Genmab Announces Financial Results for the First Half 2012 and Improves 2012
COPENHAGEN, Denmark, Nov. 7, 2012 (GLOBE NEWSWIRE) --
Interim Report for the 9 Months Ended September 30, 2012
*Entered global license and development agreement for daratumumab with
Janssen Biotech, USD 55 million (DKK 327 million) upfront payment and
agreement to purchase 5.4 million shares at a price of DKK 88 per share
*Revenue increased by 25%, operating loss reduced by 41%, cash position
*Signed DuoBody^® collaboration with Janssen Biotech
*Arzerra^® first nine months net sales increased 43% over prior year.
Guidance for Arzerra royalties for 2012 increased
"During the last nine months we have delivered on a great number of our
objectives and made very significant progress towards becoming a sustainable
company. The daratumumab collaboration with Janssen Biotech and the two
recent DuoBody deals with Novartis and Janssen Biotech have not only increased
our financial security, but also serve to build our future pipeline," said Jan
van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Financial Performance First Nine Months
*Genmab's revenues were DKK 322 million for the first nine months of 2012
compared to DKK 258 million for the corresponding period in 2011. The
increase of DKK 64 million or 25% was mainly driven by higher Arzerra
royalties in addition to revenue related to our daratumumab collaboration
with Janssen Biotech (Janssen) and the achievement of a milestone under
our collaboration with GlaxoSmithKline (GSK).
*Operating expenses decreased 3% from DKK 443 million in the first nine
months of 2011 to DKK 430 million in the first nine months of 2012.
*An operating loss of DKK 109 million in the first nine months of 2012
compared to DKK 185 million in the corresponding period for 2011, an
improvement of 41%. The improved operating result was driven by increased
revenues and continued strong focus on cost control.
*On September 30, 2012, Genmab had a cash position of DKK 1,194 million.
This represents a net increase of DKK 89 million from the beginning of
2012 which is primarily related to the upfront payment received from
Janssen and is partially offset by the ongoing investment in our research
and development activities.
Business Progress Third Quarter to Present
*July: Genmab entered into a collaboration with Janssen to create and
develop bispecific antibodies for up to 10 programs using its DuoBody
technology platform. Genmab received an upfront payment of USD 3.5
million. Genmab will potentially be entitled to milestone and license
payments of up to approximately USD 175 million per program, if all
milestones are met, plus research funding and royalties.
*August: Genmab announced a global license and development agreement for
daratumumab with Janssen. The agreement became effective after receiving
antitrust clearance under the US Hart-Scott-Rodino act in September at
which time Genmab received an upfront payment of USD 55 million (DKK 327
million at the date of the agreement). As part of the daratumumab
agreement, Johnson & Johnson Development Corporation (JJDC) agreed to
invest DKK 475 million to subscribe for 5.4 million new shares of Genmab
at a price of DKK 88 per share which was approximately 30% above Genmab's
closing share price the day before the agreement was announced. These
shares were issued in October following a formal approval of a private
placement prospectus. Genmab has received a total of DKK 800 million in
cash under the agreement so far and could also be entitled to up to USD 1
billion in development, regulatory and sales milestones, in addition to
tiered double digit royalties.
*August: Genmab announced improved financial guidance taking into account
the impact of the agreement for daratumumab.
*October: GSK reported net sales for Arzerra for the third quarter of 2012
of GBP 18.2 million, an increase of 53% over Q3 2011, resulting in royalty
income of DKK 34 million to Genmab. A large portion of Rest of the World
sales in the third quarter of 2012 are related to the supply of ofatumumab
for clinical trials run by other companies, and as such does not reflect
ongoing commercial demand.
Genmab is improving its 2012 financial guidance due to higher Arzerra royalty
income which is now expected to be in the range of DKK 105 - 115 million, an
increase of DKK 15 million compared to the previous guidance of DKK 90 - 100
Genmab will hold a conference call in English to discuss the results for the
first nine months of 2012 today, Wednesday, November 7, at 6.00 pm CET, 5.00
pm GMT or noon EST. The dial in numbers are:
+1 718 354 1226 (US participants) and ask for the Genmab conference call
+44 207 509 5139 (international participants) and ask for the Genmab
A live and archived webcast of the call and relevant slides will be available
To read the full PDF version of the Interim Report for the 9 Months Ended
September 30, 2012, visit Genmab's website at
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra^(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
T: +45 33 44 77 20; M: +45 25 12 62 60; E: email@example.com
This Company Announcement contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.
Genmab^®; the Y-shaped Genmab logo^®; HuMax^®; HuMax-CD20^®; DuoBody^®and
UniBody^® are all trademarks of Genmab A/S. Arzerra^® is a trademark of
Company Announcement no. 29
CVR no. 2102 3884
1260 Copenhagen K
Press spacebar to pause and continue. Press esc to stop.